HK1244906A1 - 藥物選擇和劑量之最佳化和個性化 - Google Patents

藥物選擇和劑量之最佳化和個性化

Info

Publication number
HK1244906A1
HK1244906A1 HK18104016.2A HK18104016A HK1244906A1 HK 1244906 A1 HK1244906 A1 HK 1244906A1 HK 18104016 A HK18104016 A HK 18104016A HK 1244906 A1 HK1244906 A1 HK 1244906A1
Authority
HK
Hong Kong
Prior art keywords
individualization
dosing
optimization
medication selection
medication
Prior art date
Application number
HK18104016.2A
Other languages
English (en)
Inventor
Tracy Glauser
Richard Wenstrup
Alexander Vinks
John Pestian
Original Assignee
Childrens Hospital Med Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Med Ct filed Critical Childrens Hospital Med Ct
Publication of HK1244906A1 publication Critical patent/HK1244906A1/zh

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Primary Health Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
HK18104016.2A 2005-11-29 2018-03-22 藥物選擇和劑量之最佳化和個性化 HK1244906A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74043005P 2005-11-29 2005-11-29
US78311806P 2006-03-16 2006-03-16

Publications (1)

Publication Number Publication Date
HK1244906A1 true HK1244906A1 (zh) 2018-08-17

Family

ID=38092744

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13103317.5A HK1176093A1 (zh) 2005-11-29 2013-03-18 藥物選擇和劑量之最佳化和個性化
HK18104016.2A HK1244906A1 (zh) 2005-11-29 2018-03-22 藥物選擇和劑量之最佳化和個性化

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13103317.5A HK1176093A1 (zh) 2005-11-29 2013-03-18 藥物選擇和劑量之最佳化和個性化

Country Status (9)

Country Link
US (4) US8589175B2 (zh)
EP (4) EP3703058A1 (zh)
JP (4) JP2009517186A (zh)
AU (1) AU2006320633A1 (zh)
CA (3) CA3060475A1 (zh)
DK (1) DK2508621T3 (zh)
ES (1) ES2529211T3 (zh)
HK (2) HK1176093A1 (zh)
WO (1) WO2007064675A2 (zh)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
WO2004074456A2 (en) 2003-02-20 2004-09-02 Mayo Foundation For Medical Education And Research Methods for selecting medications
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
CA3060475A1 (en) 2005-11-29 2007-06-07 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
GB2462218A (en) * 2006-03-10 2010-02-03 Neurotech Res Pty Ltd Subject modelling
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
US8732188B2 (en) * 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
JP4882927B2 (ja) * 2007-08-31 2012-02-22 セイコーエプソン株式会社 カテゴリ識別方法
JP2009093334A (ja) * 2007-10-05 2009-04-30 Seiko Epson Corp 識別方法及びプログラム
CA2710333A1 (en) * 2008-01-03 2009-07-09 Abbott Biotechnology Ltd. Predicting long-term efficacy of a compound in the treatment of psoriasis
US20090216561A1 (en) * 2008-02-22 2009-08-27 Swedish Health Services Methods for management of anticoagulation therapy
US20090216563A1 (en) * 2008-02-25 2009-08-27 Michael Sandoval Electronic profile development, storage, use and systems for taking action based thereon
US20090216639A1 (en) * 2008-02-25 2009-08-27 Mark Joseph Kapczynski Advertising selection and display based on electronic profile information
US9449150B2 (en) * 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US8682687B2 (en) * 2008-04-24 2014-03-25 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US20100081860A1 (en) * 2008-04-24 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US9282927B2 (en) * 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US20090271122A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US8876688B2 (en) 2008-04-24 2014-11-04 The Invention Science Fund I, Llc Combination treatment modification methods and systems
US9662391B2 (en) * 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US8615407B2 (en) * 2008-04-24 2013-12-24 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US7974787B2 (en) * 2008-04-24 2011-07-05 The Invention Science Fund I, Llc Combination treatment alteration methods and systems
US20100042578A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100076249A1 (en) * 2008-04-24 2010-03-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100030089A1 (en) * 2008-04-24 2010-02-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US9026369B2 (en) * 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US9239906B2 (en) 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20100280332A1 (en) * 2008-04-24 2010-11-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US20100004762A1 (en) * 2008-04-24 2010-01-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090270687A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for modifying bioactive agent use
US8606592B2 (en) * 2008-04-24 2013-12-10 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US9064036B2 (en) 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US9649469B2 (en) 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US9560967B2 (en) * 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US8930208B2 (en) 2008-04-24 2015-01-06 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US20100125421A1 (en) * 2008-11-14 2010-05-20 Howard Jay Snortland System and method for determining a dosage for a treatment
US20100125782A1 (en) * 2008-11-14 2010-05-20 Howard Jay Snortland Electronic document for automatically determining a dosage for a treatment
US8122820B2 (en) * 2008-12-19 2012-02-28 Whirlpool Corporation Food processor with dicing tool
US10853900B2 (en) * 2009-02-09 2020-12-01 Fair Isaac Corporation Method and system for predicting adherence to a treatment
AU2010270227B2 (en) * 2009-07-08 2015-01-22 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
US8417660B2 (en) * 2009-07-10 2013-04-09 Medimpact Healthcare Systems, Inc. Modifying a patient adherence score
US8909593B2 (en) * 2009-07-10 2014-12-09 Medimpact Healthcare Systems, Inc. Modifying a patient adherence score
US20110082867A1 (en) * 2009-10-06 2011-04-07 NeX Step, Inc. System, method, and computer program product for analyzing drug interactions
JP5562209B2 (ja) * 2009-11-04 2014-07-30 第一三共株式会社 医薬の観察研究又は疫学研究のための被験者登録方法
US20110209065A1 (en) * 2010-02-23 2011-08-25 Farmacia Electronica, Inc. Method and system for consumer-specific communication based on cultural normalization techniques
EP2567343A4 (en) 2010-05-06 2018-01-31 Atigeo Corporation Systems, methods, and computer readable media for security in profile utilizing systems
CN110391028A (zh) * 2010-08-13 2019-10-29 智能医学公司 用于生产个性化定制药物产品的系统和方法
US8676607B2 (en) 2011-01-10 2014-03-18 Medimpact Healthcare Systems, Inc. Obtaining patient survey results
US20120179481A1 (en) * 2011-01-10 2012-07-12 Medimpact Healthcare Systems, Inc. Recommending Prescription Information
US20140349862A1 (en) * 2011-05-30 2014-11-27 Vuong Ngoc Trieu Methods and compositions for therapeutic drug monitoring and dosing by point of care pharmacokinetic profiling
KR101289307B1 (ko) 2011-08-23 2013-07-24 주식회사 아리바이오 개인별 맞춤 영양제 조제 시스템
EP2754076B1 (en) * 2011-09-08 2021-03-10 Fresenius Medical Care Holdings, Inc. System and method of modeling erythropoiesis and its management
US20130268290A1 (en) * 2012-04-02 2013-10-10 David Jackson Systems and methods for disease knowledge modeling
EP2901345A4 (en) 2012-09-27 2016-08-24 Childrens Mercy Hospital GENOME ANALYSIS SYSTEM AND DIAGNOSIS OF GENETIC DISEASE
JP6412499B2 (ja) 2012-10-05 2018-10-24 ダイアン モールド 数学モデルの関数として患者特有の投与を提供するためのシステムおよび方法
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods
US9679111B2 (en) 2012-11-05 2017-06-13 Fresenius Medical Care Holdings, Inc. System and method of modeling erythropoiesis including iron homeostasis
CN105190656B (zh) 2013-01-17 2018-01-16 佩索纳里斯公司 用于遗传分析的方法和系统
US20150317449A1 (en) * 2013-01-24 2015-11-05 Kantrack Llc Medication Delivery System
KR20150113113A (ko) * 2013-01-29 2015-10-07 몰레큘러 헬스 게엠베하 임상적 판단 지원을 위한 시스템 및 방법
US20160335412A1 (en) * 2013-01-30 2016-11-17 Geoffrey Tucker Systems and methods for predicting and adjusting the dosage of medicines in individual patients
EP2951741A2 (en) * 2013-02-03 2015-12-09 Genelex Corporation Systems and methods for quantification and presentation of medical risk arising from unknown factors
US10262112B2 (en) 2013-02-04 2019-04-16 Precera Bioscience, Inc. Prescription decision support system and method using comprehensive multiplex drug monitoring
US20140229191A1 (en) * 2013-02-04 2014-08-14 Sano Informed Prescribing, Llc Prescription decision support system and method using comprehensive multiplex drug monitoring
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
US20140274763A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to pain treatments
US10853451B2 (en) * 2013-06-06 2020-12-01 Timeless Veterinary Systems International Limited Drug formulary application
KR102397974B1 (ko) * 2013-06-20 2022-05-13 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법의 제공
US20150039325A1 (en) * 2013-08-02 2015-02-05 Real Endpoints LLC Assessing Pharmaceuticals
US20150039331A1 (en) * 2013-08-02 2015-02-05 Real Endpoints LLC Assessing pharmaceuticals
EP3039161B1 (en) 2013-08-30 2021-10-06 Personalis, Inc. Methods and systems for genomic analysis
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
WO2015054234A1 (en) * 2013-10-07 2015-04-16 The University Of Chicago Genomic prescribing system and methods
US20150127372A1 (en) * 2013-11-07 2015-05-07 Quintiles Transnational Corporation Electrical Computing Devices Providing Personalized Patient Drug Dosing Regimens
US10943672B2 (en) * 2013-12-12 2021-03-09 Ab-Biotics S.A. Web-based computer-aided method and system for providing personalized recommendations about drug use, and a computer-readable medium
US20150269355A1 (en) * 2014-03-19 2015-09-24 Peach Intellihealth, Inc. Managing allocation of health-related expertise and resources
US20170177834A1 (en) * 2014-03-21 2017-06-22 The Regents Of The University Of California Nanomedicine optimization with feedback system control
US20150265628A1 (en) * 2014-03-21 2015-09-24 CompanionDx Reference Lab, LLC Genomic testing for effective therapies and determination of dosing strategy
US10565329B2 (en) 2014-06-30 2020-02-18 Evolving Machine Intelligence Pty Ltd System and method for modelling system behaviour
NZ730560A (en) * 2014-09-29 2020-05-29 Zogenix International Ltd Control system for control of distribution of medication
WO2016070131A1 (en) 2014-10-30 2016-05-06 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10534895B2 (en) * 2015-01-20 2020-01-14 Icpd Technologies, Llc System and method for ranking options for medical treatments
JP6301966B2 (ja) * 2015-03-13 2018-03-28 株式会社Ｕｂｉｃ データ分析システム、データ分析方法、データ分析のためのプログラム、及び、このプログラムの記録媒体
CA2988724C (en) * 2015-04-09 2023-10-10 Diane R. Mould Systems and methods for patient-specific dosing
KR101990951B1 (ko) * 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
US20180358129A1 (en) * 2015-11-26 2018-12-13 Koninklijke Philips N.V. System and method for educating a user about a condition of interest
WO2017112702A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
CN115273970A (zh) 2016-02-12 2022-11-01 瑞泽恩制药公司 用于检测异常核型的方法和系统
WO2017149530A1 (en) 2016-02-29 2017-09-08 Mor Research Applications Ltd System and method for selecting optimal medications for a specific patient
EP3223181B1 (en) 2016-03-24 2019-12-18 Sofradim Production System and method of generating a model and simulating an effect on a surgical repair site
EP3440580A4 (en) * 2016-04-05 2019-12-04 The Board of Trustees of the Leland Stanford Junior University TARGETED THERAPY SYSTEMS AND METHODS BASED ON THE RESPONSE TO SINGLE CELL STIMULUS DISORDER
UA126379C2 (uk) 2016-04-15 2022-09-28 Баксалта Інкорпорейтед Спосіб і пристрій для надання фармакокінетичної схеми дозування лікарських препаратів
AU2017269764A1 (en) * 2016-05-25 2018-12-13 F. Hoffmann-La Roche Ag Materials and methods relating to dosage regimen design
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
US10783997B2 (en) * 2016-08-26 2020-09-22 International Business Machines Corporation Personalized tolerance prediction of adverse drug events
MX2019002731A (es) * 2016-09-08 2019-10-02 Curematch Inc Optimizacion de opciones terapeuticas en medicina perzonalizada.
US20180121617A1 (en) * 2016-10-28 2018-05-03 Pinscriptive, Inc. Treatment Decision Interface Device and Graphical User Interface (GUI)
US20180121616A1 (en) * 2016-10-28 2018-05-03 Pinscriptive, Inc. Systems and Methods for Treatment Decisions
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
JP2018156149A (ja) * 2017-03-15 2018-10-04 オムロン株式会社 投薬支援装置、方法およびプログラム
EP3622423A1 (en) * 2017-05-12 2020-03-18 The Regents of The University of Michigan Individual and cohort pharmacological phenotype prediction platform
CN107273710A (zh) * 2017-08-22 2017-10-20 北京岙特杰诺生物科技有限公司 一种建立药物代谢酶基因与药物代谢的关系模型的方法
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11153156B2 (en) 2017-11-03 2021-10-19 Vignet Incorporated Achieving personalized outcomes with digital therapeutic applications
WO2019104101A1 (en) * 2017-11-21 2019-05-31 Verisim Life Inc. Systems and methods for full body circulation and drug concentration prediction
US11568974B2 (en) 2017-12-21 2023-01-31 Aseko, Inc. Advising diabetes medications
US11227692B2 (en) 2017-12-28 2022-01-18 International Business Machines Corporation Neuron model simulation
US20210035672A1 (en) * 2018-04-05 2021-02-04 University Of Maryland, Baltimore Method and apparatus for individualized administration of medicaments for delivery within a therapeutic range
KR20210073487A (ko) * 2018-04-23 2021-06-18 다이앤 몰드 적응성 투여 요법의 수정 시스템 및 방법
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
BR112020024917A2 (pt) * 2018-06-06 2021-03-09 Minoryx Therapeutics S.L. Método de administrar uma quantidade terapeuticamente eficaz de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona
RU2695820C1 (ru) * 2018-09-28 2019-07-29 Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический центр наркологии Департамента здравоохранения города Москвы" (ГБУЗ "МНПЦ наркологии ДЗМ") Способ прогнозирования оценки эффективности терапии трифлуоперазином для лечения расстройств, сопровождающихся развитием психотической симптоматики
US11965206B2 (en) 2018-12-21 2024-04-23 John Stoddard Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes
US11721441B2 (en) * 2019-01-15 2023-08-08 Merative Us L.P. Determining drug effectiveness ranking for a patient using machine learning
US11809382B2 (en) 2019-04-01 2023-11-07 Nutanix, Inc. System and method for supporting versioned objects
US20220223247A1 (en) * 2019-05-21 2022-07-14 Syqe Medical Ltd. Substance delivery planning system
US11676727B2 (en) 2019-08-14 2023-06-13 Optum Technology, Inc. Cohort-based predictive data analysis
IT201900024150A1 (it) 2019-12-16 2021-06-16 Persongene Srl Sistema e metodo per la determinazione di un parametro di adeguatezza di un farmaco in funzione di fattori genetici
US11443854B2 (en) * 2020-02-24 2022-09-13 International Business Machines Corporation Identifying potential medicinal interactions for online clinical trial study groups
CN111696678B (zh) * 2020-06-15 2023-05-26 中南大学 一种基于深度学习的用药决策方法和系统
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11056242B1 (en) 2020-08-05 2021-07-06 Vignet Incorporated Predictive analysis and interventions to limit disease exposure
US11127506B1 (en) 2020-08-05 2021-09-21 Vignet Incorporated Digital health tools to predict and prevent disease transmission
US11504011B1 (en) 2020-08-05 2022-11-22 Vignet Incorporated Early detection and prevention of infectious disease transmission using location data and geofencing
US11456080B1 (en) 2020-08-05 2022-09-27 Vignet Incorporated Adjusting disease data collection to provide high-quality health data to meet needs of different communities
CN112221023B (zh) * 2020-09-27 2023-12-15 中国辐射防护研究院 一种放射性药物的剂量评估系统及方法
US12001872B2 (en) 2020-10-14 2024-06-04 Nutanix, Inc. Object tiering from local store to cloud store
US11900164B2 (en) 2020-11-24 2024-02-13 Nutanix, Inc. Intelligent query planning for metric gateway
US11822370B2 (en) 2020-11-26 2023-11-21 Nutanix, Inc. Concurrent multiprotocol access to an object storage system
TWI775253B (zh) * 2020-12-24 2022-08-21 宏碁股份有限公司 高風險用藥路徑的計算方法
US11789837B1 (en) 2021-02-03 2023-10-17 Vignet Incorporated Adaptive data collection in clinical trials to increase the likelihood of on-time completion of a trial
US11586524B1 (en) 2021-04-16 2023-02-21 Vignet Incorporated Assisting researchers to identify opportunities for new sub-studies in digital health research and decentralized clinical trials
US11281553B1 (en) 2021-04-16 2022-03-22 Vignet Incorporated Digital systems for enrolling participants in health research and decentralized clinical trials
CN113345600B (zh) * 2021-05-06 2024-02-27 中国食品药品检定研究院 一种抗感染药物注射剂的有效性评价方法及其应用
CN113917025B (zh) * 2021-10-09 2024-07-19 上海市精神卫生中心（上海市心理咨询培训中心） 一种定量检测生物样本中精神类药物的试剂盒及其应用
US12032857B2 (en) 2021-11-22 2024-07-09 Nutanix, Inc. System and method for shallow copy
US11705230B1 (en) 2021-11-30 2023-07-18 Vignet Incorporated Assessing health risks using genetic, epigenetic, and phenotypic data sources
US11901083B1 (en) 2021-11-30 2024-02-13 Vignet Incorporated Using genetic and phenotypic data sets for drug discovery clinical trials
WO2023172522A1 (en) * 2022-03-07 2023-09-14 The Regents Of The University Of California Wearable aptamer microneedle patch for continuous minimally-invasive biomonitoring

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2103756T3 (es) 1990-06-22 1997-10-01 Hoffmann La Roche Deteccion de metabolizadores ineficaces de farmacos.
US5844108A (en) 1990-06-22 1998-12-01 Roche Molecular Systems, Inc. Primers targeted to NAT2 gene for detection of poor metabolizers of drugs
FI92241C (fi) 1993-01-28 1994-10-10 Sampower Oy Menetelmä vapaamäntämoottorin tärinän vaimentamiseksi ja tärinävaimennettu vapaamäntämoottori
US5833599A (en) * 1993-12-13 1998-11-10 Multum Information Services Providing patient-specific drug information
US6022683A (en) 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
EP0976070A1 (en) 1997-04-17 2000-02-02 Glaxo Group Limited Statistical deconvoluting of mixtures
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
US6653073B1 (en) 1998-02-20 2003-11-25 City Of Hope Association of the serotonin transport (HTT) gene with cardiovascular disease and longevity
JP2002510817A (ja) 1998-04-03 2002-04-09 トライアングル・ファーマシューティカルズ，インコーポレイテッド 治療処方計画の選択をガイドするためのシステム、方法及びコンピュータ・プログラム製品
JP2002518022A (ja) 1998-06-16 2002-06-25 ノヴァ モレキュラー インク． Ｂｃｈｅ遺伝子型の決定による神経疾患の治療法
WO2000020634A1 (en) 1998-10-01 2000-04-13 Nova Molecular, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
US6183963B1 (en) 1998-10-23 2001-02-06 Signalgene Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
US6861217B1 (en) 1998-11-25 2005-03-01 Genaissance Pharmaceuticals, Inc. Variation in drug response related to polymorphisms in the β2-adrenergic receptor
WO2000047771A2 (en) 1999-02-12 2000-08-17 Genset Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
WO2000050639A2 (en) 1999-02-22 2000-08-31 Variagenics, Inc. Gene sequence variations with utility in determining the treatment of disease
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
JP3777858B2 (ja) 1999-03-09 2006-05-24 株式会社エスアールエル 副甲状腺ホルモン受容体遺伝子の多型性によるｐｔｈ反応性予測方法
US6528260B1 (en) 1999-03-25 2003-03-04 Genset, S.A. Biallelic markers related to genes involved in drug metabolism
US20010034023A1 (en) 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
JP4532750B2 (ja) 1999-04-28 2010-08-25 大日本住友製薬株式会社 Ｃｙｐ２ａ６遺伝子診断法
EP1054066B1 (en) 1999-05-18 2007-10-17 Nipro Corporation Method for anticipating sensitivity to medicine for osteoporosis and a reagent therefor
US6912492B1 (en) 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6297014B1 (en) 1999-07-02 2001-10-02 Cedars-Sinai Medical Center Genetic test to determine non-responsiveness to statin drug treatment
US6338039B1 (en) 1999-07-20 2002-01-08 Michael Lonski Method for automated collection of psychotherapy patient information and generating reports and treatment plans
US20020077756A1 (en) 1999-11-29 2002-06-20 Scott Arouh Neural-network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including drug dosage estimation
GB0000896D0 (en) 2000-01-14 2000-03-08 Univ Glasgow Improved analytical chip
EP1248832A4 (en) 2000-01-21 2004-07-07 Variagenics Inc IDENTIFICATION OF GENETIC COMPONENTS IN DRUG REACTION
US6675166B2 (en) 2000-02-09 2004-01-06 The John Hopkins University Integrated multidimensional database
DE60135366D1 (de) 2000-04-18 2008-09-25 Virco Bvba Methode zur bestimmung der resistenz gegen medikamente
US6251608B1 (en) 2000-04-20 2001-06-26 Technion Research & Development Foundation, Ltd. Method of determining a potential of a hyperglycemic patients of developing vascular complications
US20020052761A1 (en) 2000-05-11 2002-05-02 Fey Christopher T. Method and system for genetic screening data collection, analysis, report generation and access
US20020010552A1 (en) 2000-05-26 2002-01-24 Hugh Rienhoff System for genetically characterizing an individual for evaluation using genetic and phenotypic variation over a wide area network
US20020076774A1 (en) * 2000-06-21 2002-06-20 Chunhua Yan Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
JP2002024385A (ja) 2000-06-30 2002-01-25 Coreflow Technologies:Kk 遺伝子情報管理システム及びその管理方法
CA2414403A1 (en) 2000-07-06 2002-01-17 The Regents Of The University Of California Methods for diagnosis and treatment of psychiatric disorders
US6461902B1 (en) * 2000-07-18 2002-10-08 Institute Of Microelectronics RF LDMOS on partial SOI substrate
WO2002012434A2 (en) 2000-08-10 2002-02-14 Glaxo Group Limited A global electronic medicine response profile testing network
US20020091680A1 (en) 2000-08-28 2002-07-11 Chirstos Hatzis Knowledge pattern integration system
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002025528A1 (en) * 2000-09-21 2002-03-28 Theradoc.Com, Inc. Systems and methods for manipulating medical data via a decision support system
US20020098498A1 (en) 2000-09-29 2002-07-25 Bader Joel S. Method of identifying genetic regions associated with disease and predicting responsiveness to therapeutic agents
US20050060102A1 (en) 2000-10-12 2005-03-17 O'reilly David J. Interactive correlation of compound information and genomic information
US6450956B1 (en) * 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
JP2002197189A (ja) 2000-12-26 2002-07-12 Sanyo Electric Co Ltd 薬品テーラーメイドシステム
US20020082869A1 (en) 2000-12-27 2002-06-27 Gateway, Inc. Method and system for providing and updating customized health care information based on an individual's genome
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
JP2002245171A (ja) 2001-02-13 2002-08-30 Canon Sales Co Inc 医療情報管理装置、その方法、プログラム、記憶媒体
US6828103B2 (en) 2001-02-22 2004-12-07 Wake Forest University Genetic polymorphisms of estrogen receptor alpha associated with favorable response to hormone replacement therapy
US20030170176A1 (en) 2001-03-14 2003-09-11 Mcgill University Individualization of therapy with antipsychotics
US20020187483A1 (en) 2001-04-20 2002-12-12 Cerner Corporation Computer system for providing information about the risk of an atypical clinical event based upon genetic information
WO2003008637A2 (en) * 2001-07-17 2003-01-30 Xanthus Life Sciences, Inc. Use of genotyping in the individualization of therapy
JP2003068878A (ja) 2001-08-23 2003-03-07 Hitachi Ltd 半導体集積回路装置およびその製造方法
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
US7461006B2 (en) 2001-08-29 2008-12-02 Victor Gogolak Method and system for the analysis and association of patient-specific and population-based genomic data with drug safety adverse event data
US20030105596A1 (en) * 2001-10-29 2003-06-05 Goldstein David Benjamin Methods for evaluating responses of a group of test subjects to a drug or other clinical treatment and for predicting responses in other subjects
AU2002363329A1 (en) 2001-11-06 2003-05-19 Elizabeth Gray Pharmacogenomics-based system for clinical applications
US20030157110A1 (en) * 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
US20030204415A1 (en) 2002-04-30 2003-10-30 Calvin Knowlton Medical data and medication selection and distribution system
US7624029B1 (en) * 2002-06-12 2009-11-24 Anvita, Inc. Computerized system and method for rapid data entry of past medical diagnoses
US20040091909A1 (en) * 2002-07-05 2004-05-13 Huang Doug Hui High throughput cytochrome P450 genotyping
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
WO2004074456A2 (en) * 2003-02-20 2004-09-02 Mayo Foundation For Medical Education And Research Methods for selecting medications
US20040193446A1 (en) * 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
WO2005017203A2 (en) 2003-07-11 2005-02-24 Yale University Systems and methods for diagnosing and treating psychological and behavioral conditions
US20050037366A1 (en) 2003-08-14 2005-02-17 Joseph Gut Individual drug safety
US20050069936A1 (en) * 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
DE10345837A1 (de) * 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Verfahren zur Bestimmung einer Wirkstoffdosierung
WO2005038049A2 (en) * 2003-10-06 2005-04-28 Heinrich Guenther System and method for optimizing drug therapy
US7813880B2 (en) * 2004-03-25 2010-10-12 University Of Maryland, Baltimore Apparatus and method for providing optimal concentrations for medication infusions
AU2005241496A1 (en) 2004-05-03 2005-11-17 Cygene Laboratories, Inc. Method and system for a comprehensive knowledge-based anonymous testing and reporting, and providing selective access to test results and report
US20050260549A1 (en) * 2004-05-19 2005-11-24 Feierstein Roslyn E Method of analyzing question responses to select among defined possibilities and means of accomplishing same
US7546285B1 (en) * 2004-09-24 2009-06-09 Sprint Communications Company L.P. System and method for scoring development concepts
KR101178463B1 (ko) * 2004-12-21 2012-09-07 아카데미아 시니카 와파린의 감도를 예측하는 유전적 변이체
AU2006205571B2 (en) 2005-01-13 2012-03-22 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
US20060280786A1 (en) * 2005-06-14 2006-12-14 Rabinow Barrett E Pharmaceutical formulations for minimizing drug-drug interactions
CA3060475A1 (en) 2005-11-29 2007-06-07 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing

Also Published As

Publication number Publication date
EP3703058A1 (en) 2020-09-02
US20140046684A1 (en) 2014-02-13
EP2508621A1 (en) 2012-10-10
CA3060475A1 (en) 2007-06-07
JP2014176718A (ja) 2014-09-25
JP5567107B2 (ja) 2014-08-06
JP5894213B2 (ja) 2016-03-23
CA2911569A1 (en) 2007-06-07
EP3223182A1 (en) 2017-09-27
EP2508621B1 (en) 2014-11-05
US8589175B2 (en) 2013-11-19
JP2013059665A (ja) 2013-04-04
AU2006320633A1 (en) 2007-06-07
WO2007064675A2 (en) 2007-06-07
JP2009517186A (ja) 2009-04-30
ES2529211T3 (es) 2015-02-18
HK1176093A1 (zh) 2013-07-19
US20090171697A1 (en) 2009-07-02
EP1958111A4 (en) 2009-07-08
US20150006190A9 (en) 2015-01-01
CA2630604C (en) 2016-01-19
US20170147779A1 (en) 2017-05-25
JP2012123837A (ja) 2012-06-28
EP1958111A2 (en) 2008-08-20
DK2508621T3 (en) 2015-01-12
WO2007064675A3 (en) 2008-11-20
CA2911569C (en) 2019-11-26
US20210166820A1 (en) 2021-06-03
CA2630604A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
HK1244906A1 (zh) 藥物選擇和劑量之最佳化和個性化
IL189671A0 (en) Medication dispenser and carrier therefor
HK1135983A1 (en) Multi-substituted pyridyl sulfoximines and their use as insecticides
IL179140A0 (en) Antibody drug conjuates and methods
EP2046391A4 (en) DRUG VECTORS, THEIR SYNTHESIS, AND METHODS FOR THEIR USE
EP2084519A4 (en) ADVANCED PRODUCTION AND MANUFACTURE OF MEDICINES
IL184659A0 (en) Antibody variants and uses thereof
SI1957073T1 (sl) Medicinsko zdravilo
IL194095A0 (en) Drug microparticles
IL217916A0 (en) Pharmaceutical products
EP1996937A4 (en) GENETIC PACKS AND USES THEREOF
SI1853605T1 (sl) Integrinski ciljni sintetični ligandi za diagnostične in terapevtske aplikacije
IL194751A0 (en) Drugs and uses
HK1136160A1 (en) Disintegrin variants and pharmaceutical uses thereof
IL185011A0 (en) Tablets with improved drug substance dispersibility
GB0516069D0 (en) Pharmaceutical and use thereof
GB0508670D0 (en) Structured packing and use thereof
ZA200610032B (en) Oculoselective drugs and prodrugs
EP1714648A4 (en) COMBINATION DRUGS
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
IL198940A0 (en) Stable s-nitrosothiols, method of synthesis and use
TWI372053B (en) Combination drug
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
GB0503296D0 (en) Procesess, production and manipulation of pharmaceutical aerosols
GB2416477B (en) Jewellery and its manufacture